Introduction And Core Principles
- Extracorporeal membrane oxygenation is a highly advanced, life-sustaining modification of cardiopulmonary bypass providing prolonged cardiac and respiratory support.
- Functions as a temporizing measure acting as a bridge to recovery, destination therapy, or cardiopulmonary transplantation.
- Deoxygenated venous blood is drained using a centrifugal pump, passed through a polymethylpentene oxygenator for gas exchange, warmed, and returned to the patient.
- The application has shifted from a salvage therapy of last resort to a preemptive, protocolized intervention.
Modalities Of Extracorporeal Support
| Modality | Physiological Support | Clinical Characteristics And Recent Advances |
|---|---|---|
| Veno-Venous (VV) | Exclusive respiratory support | Relies on native cardiac output; modern practice favors single-site, double-lumen cannulas to improve patient mobility and reduce decannulation risk. |
| Veno-Arterial (VA) | Full hemodynamic and respiratory support | Bypasses heart and lungs to unload ventricles; modality of choice for cardiogenic shock and myocarditis. |
| Hybrid (VVA/VP) | Targeted cardiorespiratory support | Veno-Veno-Arterial (VVA) optimizes upper body oxygenation; Veno-Pulmonary (VP) directly addresses isolated right ventricular failure. |
Clinical Indications And Contraindications
Primary Indications
- Respiratory indications include severe acute respiratory distress syndrome, refractory viral pneumonias, meconium aspiration syndrome, and congenital diaphragmatic hernia.
- Cardiac indications feature fulminant viral myocarditis, acute decompensated heart failure, and complex congenital heart disease.
- Extracorporeal cardiopulmonary resuscitation deployed within 30 to 45 minutes of refractory cardiac arrest yields significantly higher neurologically intact survival.
Contraindications
- Absolute contraindications include lethal chromosomal anomalies, severe irreversible brain injury, massive intracranial hemorrhage, and terminal malignancies.
- Extreme prematurity (less than 34 weeks gestation) or weight less than 2 kilograms remain strong relative contraindications due to the high risk of catastrophic intraventricular hemorrhage from systemic anticoagulation.
Recent Technological And Pharmacological Advances
Circuit Innovations
- Polymethylpentene hollow-fiber oxygenators eliminate plasma leak, lower resistance, and extend functional lifespans, reducing inflammatory responses.
- Biomimetic circuit coatings with nitric oxide-releasing polymers significantly blunt the contact activation of the coagulation cascade and systemic inflammatory response syndrome.
- Magnetically levitated centrifugal pumps drastically reduce shear stress, resulting in decreased circuit-induced hemolysis and subsequent acute kidney injury.
Anticoagulation Shift
- Massive pharmacological shift is occurring from unfractionated heparin to Bivalirudin.
- Bivalirudin provides predictable anticoagulation and is associated with a marked reduction in major hemorrhagic complications.
- Routine supplementation with Factor XIII concentrate is actively employed to mitigate refractory surgical site and mucosal hemorrhage during prolonged runs.
ELSO Guidelines And Survivorship Programs
ELSO 2025-2026 Guidelines
- Mandates continuous multimodal neuromonitoring utilizing Near-Infrared Spectroscopy, serial transcranial dopplers, and continuous electroencephalography.
- Promotes early, cautious trophic enteral feeds even with high inotrope scores to prevent gut mucosal atrophy and bacterial translocation.
Mobile Transport And Survivorship
- Primary retrieval utilizes specialized mobile teams utilizing miniaturized transport consoles to stabilize and transport the child back to apex centers.
- Up to 30% of pediatric survivors suffer from Post-Intensive Care Syndrome.
- Institutions utilize the Standardized Therapy after ECMO Program (STEP) for intentional, multidisciplinary discharge and longitudinal neurodevelopmental follow-up.